Our finding revealed that IL-6 expression is altered significantly in response to Akirin2 expression changes, indicating that Akirin2 might also regulate IL-6 expression through the NF-κB pathway in the context of CCA. The gene discussed is IL6; the disease is cholangiocarcinoma.